Ian Miscampbell, managing partner at UK-based Sixth Element Capital describes in a television interview how the CRT Pioneer Fund has established with Cancer Research Technology and the European Investment Fund to create a £50m investment fund to bridge the investment gap between cancer drug discovery and early development. It will take potential cancer drugs, primarily discovered by Cancer Research UK, from discovery through to entry to Phase II clinical trials before partnering with pharmaceutical and biotechnology companies. Sixth Element Capital was appointed to manage the fund.
Sixth Element On Bridging The Divide To Get Drugs To Patients Faster
A fund to bridge the UK financing gap between cancer drug discovery and early treatment development is managed by Sixth Element Capital and making an innovative impact.
More from Clinical Trials
• By
Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.
• By
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
• By
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
• By
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
More from R&D
• By
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
• By
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
• By
Multi-blockbuster falls short in a giant cell arteritis study.